METHODS AND PRODUCTS FOR TREATMENT OF DISEASES
The present invention relates to the treatment of diseases and conditions with an effective amount of a steroid having those formulas given in the specification, or a pharmacologically-acceptable salt or ester thereof. The disease or conditions treatable according to the invention include angiogenic diseases and conditions of the eye, angiogenic diseases and conditions of the brain, inflammatory diseases and conditions of the eye, inflammatory diseases and conditions of the brain and neurodegenerative diseases.
1 - 180 . (canceled)
181 . A pharmaceutical product suitable for treatment of the eye comprising danazol or a pharmacologically-acceptable salt or ester thereof.
182 . The product of claim 181 , wherein the product is a pharmaceutical composition formulated for treatment of the eye.
183 . The composition of claim 182 , wherein the composition is formulated for intraocular injection into the eye.
184 . The composition of claim 182 , wherein the composition is formulated for topical administration to the eye.
185 . The composition of claim 184 , wherein the composition is eye drops.
186 . The composition of claim 184 , wherein the composition is a topical ophthalmic suspension.
187 . The composition of claim 186 , wherein the ophthalmic suspension is a colloidal suspension.
188 . The composition of claim 184 , wherein the composition is a topical ophthalmic solution.
189 . The composition of claim 188 , wherein the ophthalmic solution comprises at least one of a dispersing agent, a solubilizing agent, a wetting agent, an emulsifying agent, a pH buffering agent, a preservative, a surfactant, a salt, a tonicity agent, and a suspending agent.
190 . The composition of claim 188 , wherein the ophthalmic solution comprises a vehicle selected from the group consisting of water, saline, aqueous dextrose, glycerol, and ethanol.
191 . The composition of claim 184 , wherein the composition is a topical ophthalmic gel.
192 . The composition of claim 191 , wherein the ophthalmic gel comprises a hydrophilic base.
193 . The composition of claim 191 , wherein the ophthalmic gel comprises Carpobol-940.
194 . The composition of claim 191 , wherein the ophthalmic gel comprises a combination of ethanol, water and propylene glycol in a ratio of 40:40:20.
195 . The composition of claim 191 , wherein the ophthalmic gel comprises at least one of a gelling agent, a preservative and a tonicity agent.
196 . The composition of claim 191 , wherein the ophthalmic gel comprises a gelling agent selected from the group consisting of hydroxylethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and ammoniated glycyrrhizinate.
197 . The composition of method of claim 184 , wherein the composition is a topical ophthalmic hydrogel.
198 . The composition of claim 197 , wherein the hydrogel comprises a swellable, gel-forming polymer.
199 . The composition of claim 198 , wherein the hydrogel is a thermoreversible hydrogel.
200 . The composition of claim 184 , wherein the composition is a topical ophthalmic ointment.
201 . The composition of claim 200 , wherein the ophthalmic ointment comprises a base selected from the group consisting of mineral oil, liquid lanolin, white petrolatum, polyethylene-mineral oil gel, or a combination thereof.
202 . The product of claim 181 , wherein the product is a pharmaceutical device suitable for treatment of the eye.
203 . The device of claim 202 , wherein the device is a solid carrier impregnated with the danazol or pharmacologically-acceptable salt or ester thereof.
204 . The device of claim 203 , wherein the device is a soft contact lens.
205 . The product of claim 181 , wherein the product is an ocular implant.